ArticleBMJ open2025

Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (

Aymeric Couturier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.